High Tide Inc. Common Shares (HITI) is a publicly traded Healthcare sector company. As of May 21, 2026, HITI trades at $2.43 with a market cap of $205.68M and a P/E ratio of 0.00. HITI moved +1.27% today. Year to date, HITI is -12.36%; over the trailing twelve months it is +2.55%. Its 52-week range spans $1.64 to $4.06. Analyst consensus is strong buy with an average price target of $5.62. Rallies surfaces HITI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
High Tide’s Remexian Delivers Record 7.6T Cannabis, Up 49% YoY: High Tide's German subsidiary Remexian Pharma delivered a record 7.6 tonnes of medical cannabis in Q2 ended April 30 2026, marking a 21% sequential and 49% year-over-year increase. Germany imported 201.1 tonnes in 2025, with Remexian now controlling over 10% of national import volumes.
| Metric | Value |
|---|---|
| Price | $2.43 |
| Market Cap | $205.68M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.06 |
| 52-Week Low | $1.64 |
| Volume | 1.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover HITI: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.62.